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Summary The development of tuberculosis-related bowel obstruction or pseudo-obstruction
during anti-tuberculosis therapy is rarely reported in immunocompetent patients. A 44-year-old
male, who had neither HIV infection nor diabetes, was hospitalized because of pulmonary
tuberculosis in November 2006. Three months after starting anti-tuberculosis therapy, he was
admitted for suspected mechanical bowel obstruction. An emergency exploratory laparotomy
showed distended bowel loops, andmultiple skip lesions from the terminal ileum to the ascending
colon. PCR analyses showed Mycobacterium tuberculosis. The therapy regimen was unchanged
after the operation; the patient gradually improved over the course of a month and was
discharged without further symptoms thereafter.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Bowel obstructions or pseudo-obstructions are uncommon
but potentially life-threatening complications of abdominal
tuberculosis.1 Only rare cases of abdominal tuberculosis
developing during anti-tuberculosis therapy have been
reported, and bowel obstructions or pseudo-obstructions* Corresponding author. No. 1, Lane 303, Changsha Street, Taitung,
Taiwan. Tel.: +886 89 310150; fax: +886 89 321240.
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doi:10.1016/j.ijid.2008.09.016are even rarer. Most such cases have involved immunocom-
promised patients. We report a patient who developed
breakthrough abdominal tuberculosis while on anti-tubercu-
losis therapy and despite being immunocompetent.
Case report
A 44-year-old male was hospitalized with chronic cough,
fever and weight loss in November 2006. Pulmonary tuber-
culosis was diagnosed, and isoniazid, rifampin and ethambu-
tol were prescribed. Cultures of sputum revealed M.Published by Elsevier Ltd. All rights reserved.
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agents. Medication was given using the directly observed
treatment, short-course (DOTS) method.
Three months later, the patient complained of vomiting,
abdominal fullness and dull pain. On physical examination,
he had periumbilical tenderness and peritoneal signs. Lym-
phopenia (228/ml) was revealed. A plain abdominal X-ray
showed air-fluid levels with small intestine distension and
absent colon gas. Abdominal computed tomography showed
asymmetric thickening of the ileocecal valve and medial wall
of the cecum; there were adjacent enlarged hypodense
lymph nodes (Figure 1). An emergency exploratory laparot-
omy showed distended bowel loops with ascites, andmultiple
skip lesions from the terminal ileum to the ascending colon.
Bowel decompression and appendectomy were performed.
Histology of a nodule from a skip lesion of the external ilealFigure 2 Histology of skip nodule lesions of the external ileal
wall and appendix, revealing chronic inflammation and fibrosis
with a few tiny non-caseating granulomas. Acid fast, GMS and PAS
are negative for microorganisms. There is no evidence of malig-
nancy (1000).
Figure 1 Abdominal computed tomography showing asym-
metric thickening of the ileocecal valve and medial wall of
the cecum (black arrows), with bowel obstruction and adjacent
enlarged hypodense lymph nodes.wall and appendix revealed non-caseating granulomas
(Figure 2). No acid-fast organisms were detected, but PCR
showed M. tuberculosis. There was no evidence of HIV
infection or any other underlying illness. The same anti-
tuberculosis therapy was continued and the patient gradually
improved over one month. He was discharged 40 days after
admission. He remained healthy with no further symptoms
thereafter.
Discussion
This patient’s case is quite unusual, in that he was immuno-
competent and receiving adequate treatment with appro-
priate drugs for a sensitive organism, but developed
breakthrough abdominal tuberculosis. The intestinal involve-
ment was such that pseudo-obstruction occurred. The diag-
nosis was unsuspected before surgery and only confirmed by
the pathology findings. Although acid-fast organisms were
not seen, PCR of material from the non-caseating granulomas
confirmed the diagnosis. PCR is in fact effective in diagnosing
abdominal tuberculosis, particularly when specimens are
small and might therefore contain very few bacteria. In
one study of 50 samples, the diagnosis of abdominal tuber-
culosis was made by histopathology in 31 cases and by PCR in
30 cases.2
It is quite unusual for abdominal tuberculosis to present
while a patient is on anti-tuberculosis therapy. Kasahara
et al. reported a case of tuberculous peritonitis after the
patient had received five months of treatment.3 Leung et al.
reported a similar case resulting in intestinal perforation.4
The pathogenesis in these cases was unclear. The authors
speculated that there might have been drug resistance, poor
drug compliance, an inadequate regimen, an immunocom-
promised host or poor drug delivery to the lymph nodes.
None of these possibilities seems to explain the break-
through disease in our patient. The M. tuberculosis isolated
from his sputum was sensitive to all anti-tuberculosis agents
and he had negative sputum cultures after treatment began.
Because his treatment was directly observed, poor compli-
ance should not have been a problem. There was no evidence
that he was immunocompromised, including HIV infection or
diabetes. Because sensitivity testing of the original culture
showed no evidence that the pathogen was resistant, the
same regimen was continued after surgery and the patient
recovered fully. This argues against poor delivery of the drug
or inadequate treatment.
In the absence of more obvious reasons, several other
mechanisms might be considered. A paradoxical response to
treatment was first described in 1984.5 This is defined as
clinical or radiological worsening of pre-existing tuberculous
lesions or the development of new lesions after a patient
starts to improve on appropriate therapy. The worsening
should not be expected in the normal course of the disease
and it must occur at least two weeks after the initiation of
treatment.6 Urakami suggested that a paradoxical response
might be caused by an allergic reaction of the host to the
tubercle bacilli.7 A paradoxical reaction might occur in either
pulmonary or extrapulmonary areas.8 Cheng et al. discussed
possible risk factors for such a reaction in patients who were
HIV negative, including perhaps a low lymphocyte count or an
initial extrapulmonary tuberculosis infection.9 This case did
indeed meet the definition of paradoxical reactions; the
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cannot rule out the presence of abdominal involvement in our
patient when he was initially diagnosed with pulmonary
tuberculosis. But he certainly did not have any abdominal
symptoms until three months into his treatment. Ha et al.
reported that bowel obstruction might develop during anti-
tuberculosis therapy in patients with abdominal tuberculosis
because of fibrosis and scarring.10 This was not mentioned in
our patient’s pathology report, but it might be a moot point.
Anand et al. reported clinical and radiological resolution
of tuberculous bowel strictures with drug therapy in 39
patients. Only 3 cases (8%) needed surgery.11 We did not
suspect the diagnosis of abdominal tuberculosis break-
through before surgery, because the patient was on anti-
tuberculosis therapy. Exploratory laparotomy was indicated
because of the suspicion of mechanical bowel obstruction.
There was no definite mechanical obstruction lesion and
pseudo-obstruction was diagnosed. We maintained medical
treatment after bowel decompression and the patient had a
complete recovery.
In conclusion, abdominal tuberculosis breakthrough while
receiving apparently adequate anti-tuberculosis treatment
does occasionally occur. A patient being treated for tuber-
culosis might have abdominal symptoms for any of a number
of reasons, but abdominal tuberculosis should not be
excluded from the differential diagnosis simply because
the patient is on adequate therapy. Our case also illustrates
that, if breakthrough occurs, the treatment regimen does not
necessarily have to be changed in the absence of evidence
that resistance has developed.
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